Ronald M Sobecks MD
Professor of Medicine, Case Western Reserve University School of Medicine
Join to View Full Profile
9500 Euclid Ave, CA60Cleveland, OH 44195
Phone+1 216-445-4626
Fax+1 216-444-9464
Dr. Sobecks is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Ronald Sobecks is a Professor of Medicine and a hematologist/oncologist at the Cleveland Clinic's Taussig Cancer Center in Cleveland, OH. He received his medical degree from Case Western Reserve University School of Medicine and has been in practice 24 years. His clinical practice and research has been with blood and marrow transplantation with hematologic malignancies.
Education & Training
University of ChicagoFellowship, Hematology and Medical Oncology, 1996 - 1999
Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Internal Medicine, 1993 - 1996
Case Western Reserve University School of MedicineClass of 1993
Certifications & Licensure
OH State Medical License 1995 - 2028
FL State Medical License 2016 - 2018
IL State Medical License 1996 - 1999
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2011, 2013-2017
- CMS Meaningful Use Stage Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2011, 2013-2017
- CMS Meaningful Use Stage Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2011, 2013-2017
Clinical Trials
- Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma Start of enrollment: 2003 Sep 01
- Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma Start of enrollment: 2009 Jun 11
- Selecting a Favorable KIR Donor in Unrelated HCT for AML Start of enrollment: 2011 Jun 01
Publications & Presentations
PubMed
- 1 citationsComparative Outcomes of Intensive Chemotherapy Versus Venetoclax Plus Hypomethylating Agents in Acute Myeloid Leukemia Patients Aged 60-75 Years: A Propensity Score-Ad...Moath Albliwi, Emily C Zabor, John Hanna, Jessica El-Asmar, Daniel P Nurse
Clinical Lymphoma, Myeloma & Leukemia. 2026-01-01 - CHARM is Prognostic of Geriatric Morbidity and Toxicity after Allogeneic Transplant for Older Adults: BMT CTN 1704 Study.Andrew S Artz, Brent R Logan, Wael Saber, Nancy Geller, Anna Bellach
Blood Advances. 2025-11-21 - Infections in steroid-refractory chronic graft versus host disease patients treated with ruxolitinib, ibrutinib, or belumosudil.Victoria Stepanyants, Hong Li, Danielle Cenin, Jessi Edwards, Claudio Brunstein
Bone Marrow Transplantation. 2025-10-01
Journal Articles
- Effect of Bone Marrow CD34+Cells and T-cell Subsets on Clinical Outcomes After Myeloablative Allogeneic Hematopoietic Cell TransplantationDeepa Jagadeesh, Matt Kalaycio, Brian Bolwell, Betty K Hamilton, Brian Hill, Brad Pohlman, Robert Dean, Navneet S Majhail, Sagar S Patel, Rabi Hanna, Aaron T Gerds, Ro..., Nature
- Neutropenic Fever During Peripheral Blood Progenitor Cell Mobilization Is Associated with Decreased CD34+ Cell Collection and Increased Apheresis Collection DaysMat Kalaycio, Robert Dean, Jack Khouri, Brad Pohlman, Aleksandr Lazaryan, Edward Copelan, Steven Andresen, Ronald Sobecks, Hien Liu, Journal of Clinical Apheresis
Abstracts/Posters
- Interactions between Donor Activating Killer Immunoglobulin-like Receptors (KIRs) and Somatic Mutations and Their Association with Outcomes after Allogeneic Hematopoie...Ronald Sobecks, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Feedback Responses of the Pyrimidine Metabolism Network Mediate Resistance to Decitabine and 5-AzacytidineRonald Sobecks, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Outcomes and Factors Impacting Use of Axicabtagene Ciloleucel in Refractory and Relapsed Large B-Cell Lymphoma: An Intent-to-Treat AnalysisRonald Sobecks, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Stem Cell Transplant in Patients with Myelodysplastic Syndromes: On Behalf of the CIBMTR Ch...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Association of MHC Class I Chain-Related Gene a (MICA) Polymorphisms with Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Letter to Editor Intravenous Compared to Oral Busulfan with Cyclophosphamide for Autologous Hematopoietic Cell Transplant Conditioning for Plasma Cell MyelomaApril 24th, 2018
ASH 2018: Dec 1-4December 1st, 2017
Cleveland Clinic Cancer DoctorNovember 13th, 2016
Professional Memberships
- Member
- Member
- American Society of Blood and Marrow TransplantationMember
- Center of International Blood and Marrow Transplant ResearchMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
